CLR 325

Drug Profile

CLR 325

Alternative Names: CLR325

Latest Information Update: 24 Jun 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Heart failure therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure

Most Recent Events

  • 01 May 2016 Phase-II clinical trials in Heart failure in USA (IV)
  • 08 Mar 2016 Novartis plans a phase II trial for Heart failure in USA (NCT02696967)
  • 01 Feb 2016 Preclinical trials in Heart failure in USA (IV) prior to February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top